Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.
Key details from the 8-K filing:
- The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
- Headquartered in Norwest, NSW, Australia
- Joel Latham serves as Chief Executive Officer and President
- The company has elected emerging growth company status
- The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs
This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.